Cellect Biotechnology logo

APOP - Cellect Biotechnology Share Price

$1.88 -0.0  -1.6%

Last Trade - 25/11/20

Sector
Healthcare
Size
Micro Cap
Market Cap £3.26m
Enterprise Value £-1.98m
Revenue £n/a
Position in Universe 5932nd / 6430
Bullish
Bearish
Unlock APOP Revenue
Momentum
Relative Strength (%)
1m -6.83%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -72.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 13.1
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CellectBiotechnology Ltd revenues was not reported. Net lossincreased 92% to NIS11.4M. Higher net loss reflects Netfinancing income/expense decrease from NIS7.1M (income) toNIS3.8M (expense). Basic Earnings per Share excludingExtraordinary Items decreased from -NIS0.03 to -NIS0.05.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APOP Revenue Unlock APOP Revenue

Net Income

APOP Net Income Unlock APOP Revenue

Normalised EPS

APOP Normalised EPS Unlock APOP Revenue

PE Ratio Range

APOP PE Ratio Range Unlock APOP Revenue

Dividend Yield Range

APOP Dividend Yield Range Unlock APOP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APOP EPS Forecasts Unlock APOP Revenue
Profile Summary

Cellect Biotechnology Ltd is an Israel-based biotechnology company. Its technology platform, ApoGraft, selects stem cells to improve the safety and efficacy of regenerative medicine and cell therapies by using functional selection. Efficient selection enables retention of most of the stem cells while neutralizing harmful mature cells. ApoGraft exploit a functional characteristic of stem cells relating to apoptosis, which is the process of programmed cell death and is a vital part of physiological development and homeostasis of all organisms. Stem cells flourish in an environment where normal cells die because their main role is reconstitution of damaged tissue. The platform is being tested for clinical use in allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematological malignancies. Additionally, the Company is developing its first product based on its platform, the ApoTainer selection kit that utilizes FasL-coated paramagnetic beads.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated August 4, 1986
Public Since November 1, 1989
No. of Shareholders: n/a
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market (Dual Listing)
Shares in Issue 2,279,973
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APOP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APOP
Upcoming Events for APOP
Frequently Asked Questions for Cellect Biotechnology
What is the Cellect Biotechnology share price?

As of 25/11/20, shares in Cellect Biotechnology are trading at $1.88, giving the company a market capitalisation of £3.26m. This share price information is delayed by 15 minutes.

How has the Cellect Biotechnology share price performed this year?

Shares in Cellect Biotechnology are currently trading at $1.88 and the price has moved by -23.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cellect Biotechnology price has moved by -32.65% over the past year.

What are the analyst and broker recommendations for Cellect Biotechnology?

There are no analysts currently covering Cellect Biotechnology.

When will Cellect Biotechnology next release its financial results?

Cellect Biotechnology is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Cellect Biotechnology dividend yield?

Cellect Biotechnology does not currently pay a dividend.

Does Cellect Biotechnology pay a dividend?

Cellect Biotechnology does not currently pay a dividend.

When does Cellect Biotechnology next pay dividends?

Cellect Biotechnology does not currently pay a dividend.

How do I buy Cellect Biotechnology shares?

To buy shares in Cellect Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cellect Biotechnology?

Shares in Cellect Biotechnology are currently trading at $1.88, giving the company a market capitalisation of £3.26m.

Where are Cellect Biotechnology shares listed? Where are Cellect Biotechnology shares listed?

Here are the trading details for Cellect Biotechnology:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: APOP
What kind of share is Cellect Biotechnology?

Based on an overall assessment of its quality, value and momentum, Cellect Biotechnology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cellect Biotechnology share price forecast 2020?

Shares in Cellect Biotechnology are currently priced at $1.88. At that level they are trading at 18.8% discount to the analyst consensus target price of 0.00.

Analysts covering Cellect Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of -377.946 for the next financial year.

How can I tell whether the Cellect Biotechnology share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cellect Biotechnology. Over the past six months, the relative strength of its shares against the market has been -44.34%. At the current price of $1.88, shares in Cellect Biotechnology are trading at -22.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cellect Biotechnology PE Ratio?

We were not able to find PE ratio data for Cellect Biotechnology.

Who are the key directors of Cellect Biotechnology?

Cellect Biotechnology's management team is headed by:

David Grossman - NED
Abraham Nahmias - IND
Michael Berelowitz - DRC
Who are the major shareholders of Cellect Biotechnology?

Here are the top five shareholders of Cellect Biotechnology based on the size of their shareholding:

Empery Asset Management, L.P. Investment Advisor/Hedge Fund
Percentage owned: 8.26% (323k shares)
Heights Capital Management, Inc. Investment Advisor
Percentage owned: 7.8% (305k shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 5.68% (222k shares)
Kasbian (Nuriel Chirich) Individual Investor
Percentage owned: 4.37% (171k shares)
Yarkoni (Shai) Individual Investor
Percentage owned: 3.64% (142k shares)
Similar to APOP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.